. Author manuscript; available in PMC: 2014 Feb 1.

Published in final edited form as: Bone Marrow Transplant. 2013 Feb 18;48(8):1056–1064. doi: 10.1038/bmt.2012.284

Table 3c.

Univariate probabilities of outcomes by donor type

	HLA-identical sibling		Other related		Unrelated		P-value

Outcome event	N eval.	Prob (95% CI)^a	N eval.	Prob (95% CI)^a	N eval.	Prob (95% CI)^a
ANC > 0.5 × 10⁹/L	50		23		38
@ 28 days		86 (72-93)		87 (64-96)		76 (59-87)	0.4703
@100 days		92 (80-97)		87 (64-96)		95 (81-99)	0.6149
Platelets > 20 × 10⁹ /L	39		19		37
@ 60 days		65 (48-78)		63 (38-80)		45 (27-61)	0.199
@100 days		68 (50-81)		63 (38-80)		51 (32-66)	0.3311
Acute GVHD, Grades 2-4	51		19		33
@100 days		25 (15-38)		21 (7-41)		36 (20-52)	0.4306
@ 180 days		25 (15-38)		21 (7-41)		40 (23-56)	0.2802
Chronic GVHD	53		21		38
@ 1 year		12 (5-22)		19 (6-38)		14 (5-27)	0.7333
@ 3 years		12 (5-22)		24 (9-43)		14 (5-27)	0.489
@5 years		12 (5-22)		24 (9-43)		14 (5-27)	0.489
Transplant-related mortality	55		21		39
@ 100days		18 (9-29)		19 (6-38)		18 (8-31)	0.9944
@ 1 year		24 (14-36)		34 (15-54)		21 (10-34)	0.5397
@ 3 years		26 (15-38)		34 (15-54)		21 (10-34)	0.5397
@ 5 years		26 (15-38)		34 (15-54)		21 (10-34)	0.5436
Relapse	55		21		39
@ 1 year		30 (18-42)		15 (4-33)		63 (46-76)	<.0001
@ 3 years		52 (38-64)		25 (9-45)		66 (49-79)	0.0043
@ 5 years		56 (41-68)		31 (13-51)		66 (49-79)	0.0263
Disease-free survival	55		21		39
@ 1 year		47 (33-59)		51 (28-70)		16 (7-29)	0.0007
@ 3 years		22 (12-34)		41 (20-61)		13 (5-26)	0.079
@ 5 years		19 (10-30)		35 (15-55)		13 (5-26)	0.2133
Overall survival	74		29		40
@ 1 year		63 (51-73)		60 (39-75)		40 (25-55)	0.0529
@ 3 years		30 (19-41)		48 (28-65)		16 (7-29)	0.0175
@ 5 years		22 (13-33)		33 (16-52)		16 (7-29)	0.3101